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Abstract Protein translocation across the cytoplasmic mem-
brane of Escherichia coli is mediated by the integral membrane
complex SecYEG and the peripherally bound ATPase SecA. To
probe the environment of the cytoplasmic domains of SecY with-
in the SecYEG complex, we introduced single cysteine residues
in each of the six cytoplasmic domains. Neighbouring SecY
molecules with a single cysteine residue in cytoplasmic domains
C1, C2 or C6 formed a disul¢de bond upon oxidation. The
presence of the disul¢de bond between two C2 domains revers-
ibly inhibited protein translocation. Chemical crosslinking
showed that the C2 and C3 domains are in close proximity of
SecG and chemical modi¢cation of the cysteine residue in the
C5 domain with N-ethyl-maleimide or £uorescein-5-maleimide
inactivates the SecYEG complex. Taken together, our data give
novel insights in the interactions between subunits of the
SecYEG complex and emphasise the importance of cytoplasmic
domain C5 for SecY functioning. + 2002 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
The heterotrimeric membrane protein complex SecYEG
forms the protein conducting channel through which precur-
sor proteins are translocated across the prokaryotic cytoplas-
mic membrane. Together with the peripheral motor protein
SecA, SecYEG constitutes a multisubunit complex termed
‘translocase’. SecA binds to the SecYEG complex and powers
the translocation process by undergoing multiple conforma-
tional changes upon binding and hydrolysis of ATP (for a
recent review see [1]).
Electron microscopy studies have revealed that multiple
SecYE(G) protomers assemble into an oligomeric complex
with a pore like structure that resembles the eukaryotic
Sec61KLQ complex [2^6]. Biochemical evidence for an oligo-
meric assembly of SecYEG comes from disul¢de crosslinking
[7,8], analytical ultracentrifugation, 2D crystallography [9]
and Blue-native gel electrophoresis studies (BN-PAGE) [10].
Oligomerisation of SecYEG was shown to be triggered by
SecA [4] but the exact oligomeric state of SecYEG during
translocation remains a topic of debate [4,10,11].
Over the years, genetic and biochemical experiments have
given a substantial insight in the interactions between the
di¡erent subunits (for a recent review see [12]). In short,
SecE interacts with domains of SecY located in the cytoplasm
[13,14], the transmembrane region [7,8], and the periplasm
[15,16]. Furthermore, SecE is involved in the association of
two SecYEG protomers [8]. Disul¢de crosslinking of SecE to
a neighbouring SecE or SecY molecule inactivates SecYEG,
indicating that dynamics of SecE are required during protein
translocation [7,8,16].
A direct interaction between SecY and SecA has been dem-
onstrated by aspeci¢c crosslinking studies [17], but so far no
site-speci¢c crosslinks have been reported. Genetic studies
with cold-sensitive SecY mutants have indicated that the
two carboxy-terminal cytoplasmic domains of SecY are in-
volved in an interaction with SecA [18^20]. On the basis of
studies with SDS-denatured SecY [21] and peptide antibodies
[22] it has been proposed that SecA also interacts with the
extreme amino-terminal region of SecY.
SecG is an auxiliary translocase component that strongly
facilitates translocation [23^25] and has been shown to be
involved in membrane cycling of SecA [26,27]. SecG forms a
stable complex with SecYE [28] that can be puri¢ed via a⁄n-
ity tags on both SecY and SecE [29,30]. Within the SecYEG
complex, SecG can form homodimers that remain associated
and even undergo topology inversion during protein translo-
cation [31,32], but the position of SecG with respect to SecY
and SecE within the SecYEG complex has remained obscure.
Likewise, the domains of SecY involved in the association of
SecYEG protomers have never been determined.
In order to understand the molecular mechanism of protein
translocation, more detailed structural information on the in-
teractions between the individual subunits within the SecA/
SecYEG complex is required. In this study, we have investi-
gated the cytoplasmic side of SecY by introducing single cys-
teine residues and performing cysteine-speci¢c labeling and
crosslinking experiments. The results are discussed with re-
spect to the interactions between the individual subunits and
the oligomeric assembly of SecYEG.
2. Materials and methods
2.1. Chemicals and biochemicals
M-Maleimidobenzoyl-N-hydroxysuccinimide ester (S-MBS) was
purchased from Pierce (Rockford, IL, USA), dithiothreitol (DTT)
from Roche (Basel, Switzerland), £uorescein-5-maleimide (F-Mal)
and Alexa-£uor0 633 C5-maleimide (AF633) from Molecular Probes
(Eugene, OR, USA). All other chemicals were purchased from Sigma
(St. Louis, MO, USA). SecA [33], SecB [34] and proOmpA [35] were
puri¢ed essentially as described. Antibodies against the C-terminus of
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SecG were a kind gift from Hajime Tokuda (University of Tokyo,
Tokyo, Japan).
2.2. Bacterial strains, growth conditions and isolation of inner
membrane vesicles (IMVs)
Escherichia coli strain DH5-K was used for standard DNA manip-
ulations. Expression of SecYEG was performed in E. coli SF100.
IMVs were isolated as described previously [7] except that all steps
were performed in 50 mM HEPES/NaOH pH 7.0, 2 mM DTT. Mem-
branes were stored at a protein concentration of 10 mg/ml in the same
bu¡er supplemented with 20% (v/v) glycerol.
2.3. Plasmids
Vector pEK1 containing the cysteine-less secY gene was created by
ligating a NcoI^ClaI fragment from pET607 [7] into pET401, resulting
in pEK1. pET401 is a pBluescript SK+ (Stratagene, La Jolla, CA,
USA) derivative, from which the PstI, SmaI and ApaI sites were
removed and a NcoI site was introduced (K.H.M. van Wely, unpub-
lished results). SecY point mutations were introduced with the Stra-
tagene QuikChange1 mutagenesis kit using pEK1 as template. Mu-
tant secY genes were recombined with (cysteine-less) secE and secG
genes by exchanging a NcoI^ClaI fragment with pET607, resulting in
the plasmids listed in Table 1. All mutations were con¢rmed by se-
quence analysis.
2.4. Labeling of cysteines
Before each labeling or crosslinking experiment, IMVs were incu-
bated with 5 mM DTT (30 min, 37‡C). Subsequently, IMVs were
diluted with 1 ml de-aerated ice-cold 50 mM HEPES/NaOH pH 7.0
and pelleted in a TLA100.2 rotor (20 min, 90 000 rpm). Labeling of
the cysteines was performed immediately after resuspension of the
membrane pellets in 50 mM HEPES/NaOH pH 7.0 with either
1 mM NEM or 0.25 mM F-Mal for 15 min at 20‡C. Labeling reac-
tions were quenched by addition of a 10-fold excess of DTT and
membranes were re-isolated as described above. F-Mal-labeled inner
membrane proteins were visualised by in gel UV £uorescence on a
Roche Lumi-Imager F1 using a cut-o¡ ¢lter of 520 nm.
2.5. Crosslinking
Before crosslinking, IMVs were treated with DTT and re-isolated as
described. Oxidative crosslinking was performed with 1 mM tetrathi-
onate (S4O6) (30 min, 37‡C). Cleavage of disul¢de bonds (re-reduc-
tion) was performed identically to the reduction procedure described.
Chemical crosslinking was performed with 1 mM S-MBS (15 min,
20‡C). Reactions were quenched with 100 mM Tris^HCl pH 8.0,
10 mM DTT.
2.6. Translocation assays
In vitro translocation reactions were performed essentially as de-
scribed [36]. Brie£y, 2 Wg of IMVs was incubated at 37‡C in bu¡er A
(50 mM HEPES/NaOH pH 7.0, 20 mM NaCl, 5 mM MgCl2, 0.1 mg/
ml BSA, 10 mM DTT) with £uorescent proOmpA (1.25 Wg/ml), SecA
(10 Wg/ml), SecB (35 Wg/ml), 0.5 mM ATP, 10 mM phosphocreatine
and 50 Wg/ml creatine kinase. F-Mal or AF633-labeled pro-
OmpA(C302S) was used as the substrate (J. de Keyzer et al., manu-
script in preparation). DTT was omitted from bu¡er A in transloca-
tion reactions with oxidised membranes. After 7 min at 37‡C,
translocation reactions were terminated by chilling on ice and un-
translocated proOmpA was digested by proteinase K (0.1 mg/ml,
15 min, 4‡C). Protease-protected material was precipitated with 5%
TCA, washed with ice-cold acetone and separated by 12% SDS^
PAGE. Fluorescent proOmpA was visualised by in gel UV £uores-
cence on a Roche Lumi-Imager F1 using a cut-o¡ ¢lter of 520 nm
(F-Mal-labeled proOmpA) or 645 nm (AF633-labeled proOmpA).
2.7. Miscellaneous
SDS^PAGE and Western blotting were performed according to
standard protocols. Protein concentrations were determined with the
Bio-Rad RC DC protein assay kit using BSA as a standard. Pro-
OmpA-stimulated SecA ATPase assays were performed as described
[7].
3. Results
3.1. Construction and chemical modi¢cation of single cysteine
residues in SecY
To probe for intermolecular interactions at the cytoplasmic
side of SecYEG by thiol chemistry, we introduced single cys-
teine residues in each of the six cytoplasmic domains of SecY
(C1 to C6, see Fig. 1). To ensure accessibility of the intro-
duced cysteine residues the positions were selected in the mid-
dle of each domain. In the selection process, highly conserved
residues or positions harbouring cold-sensitive or prl muta-
tions were avoided and where possible serine residues were
replaced. In this way, six single cysteine SecY mutants (Table
1) were constructed that were introduced into a cysteine-less
secYEG expression system [7].
Inverted membrane vesicles (IMVs) were isolated from
E. coli SF100 cells that overproduced the mutant SecYEG
complexes. For all cysteine mutants the expression levels of
SecYEG and the amount of SecA associated with the mem-
branes were similar to that of the Cys-less control. Further-
more, the proOmpA-stimulated SecA ATPase activity (data
not shown) and the in vitro translocation of proOmpA (Fig.
3A) were indistinguishable from the cysteine-less control. We
have previously shown that due to the high expression levels
achieved with our expression system, the background activity
of chromosomally encoded SecYEG is negligible as compared
to the plasmid-encoded SecYEG [7,37]. Taken together, this
indicates that the introduced cysteines do not alter the expres-
sion nor the functionality of the SecYEG complex.
To check the accessibility of the introduced cysteines for
thiol modifying reagents, we incubated IMVs harbouring the
mutant SecYEG complexes with the thiol reactive probe
F-mal. Except for the Cys-less control, all single cysteine mu-
tants show a prominent £uorescent band (Fig. 2) correspond-
ing to SecY as con¢rmed by Western blotting (data not
shown). Due to the high expression levels of SecY(EG), back-
ground labeling of other membrane proteins is negligible. Pre-
treatment of the membranes with NEM completely prevented
F-Mal labeling (data not shown). These results show that all
Table 1
Overview of plasmids used in this study
Plasmid Relevant characteristics SecY mutation Source
pET401 pBluescript SK+ derivative ^ K.H.M. van Wely (unpublished results)
pET607 cysteine-less secYEG in pET610 ^ [7]
pEK1 cysteine-less secY in pET401 ^ this work
pEK20 cysteine-less secYEG ^ this work
pEK21 secY(S11C)EG S11C (AGTCTGT) this work
pEK22 secY(S111C)EG S111C (TCTCTGT) this work
pEK23 secY(T179C)EG T179C (ACTCTGT) this work
pEK24 secY(S262C)EG S262C (AGCCTGC) this work
pEK25 secY(S349C)EG S349C (TCCCTGC) this work
pEK26 secY(S431C)EG S431C (TCTCTGT) this work
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the introduced cysteine residues are accessible for the thiol
modifying reagents NEM and F-Mal. Furthermore, by using
F-Mal as a second round labeling agent, this assay provides a
simple tool to assess SecY modi¢cation by non-£uorescent
thiol reactive probes.
3.2. ProOmpA translocation into IMVs containing chemically
modi¢ed SecYEG
To investigate if chemical modi¢cation of the cytoplasmic
cysteine residues a¡ects the functionality of the SecYEG com-
plex, IMVs containing the di¡erent SecYEG mutants were
treated with NEM (molecular weight (MW) 125 Da) or
F-Mal (MW 427 Da). Subsequently, the IMVs were assayed
for in vitro translocation activity of proOmpA(C302S) labeled
with F-Mal (proOmpA-F-Mal) or with AF633 (proOmpA-
AF633). Both these £uorescent precursors behave indistin-
guishably from unlabeled proOmpA as shown by SecA ATP-
ase activity assays and immunodetection (J. de Keyzer et al.,
manuscript in preparation) and can thus replace iodinated
proOmpA. To avoid interference of the (pro)OmpA-F-Mal
signal(s) with that of F-Mal-labeled inner membrane proteins
we used proOmpA-AF633 in the translocation assays with
F-Mal-labeled SecY(EG) complexes. (AF633 can be detected
above 645 nm where the emission of £uorescein is negligible).
NEM or F-Mal modi¢cation of SecY(S349C)EG vesicles
(C5 domain) completely abolishes proOmpA translocation
(Fig. 3B,C, lane 6) and strongly inhibits the proOmpA-stimu-
lated SecA ATPase activity (data not shown). Interestingly,
NEM modi¢cation of the other mutants has no e¡ect on
proOmpA translocation, but labeling of IMVs containing
SecY(S11C)EG (domain C1), SecY(S111C)EG (domain C2)
and SecY(S431C)EG (domain C6) with the considerably larg-
er probe F-Mal partially inhibits proOmpA translocation
(Fig. 3C, lanes 2, 3 and 7). Taken together, these results in-
dicate that particularly cytoplasmic domain C5 is highly sen-
sitive for chemical modi¢cation.
3.3. Oxidative crosslinking of SecY within an oligomeric
SecYEG complex
Several studies indicated that SecYE(G) protomers form
oligomeric complexes. For this reason we investigated if the
single cysteine SecY mutants can form disul¢de bonds upon
oxidation. IMVs were incubated with the reducing agent DTT
(Fig. 4A) or with the oxidising agent tetrathionate (S4O6)
(Fig. 4B), and analysed by SDS^PAGE followed by immuno-
detection with an antibody raised against SecY. Upon oxida-
tion, SecY mutants S11C, S111C and S431C (in C1, C2 and
C6, respectively) gave rise to a pronounced crosslink product
of 75 kDa (Fig. 4B, lanes 2, 3 and 7). The formation of this
product is reversible by DTT and can be prevented by pre-
treatment of the cysteines with NEM, indicating that the
crosslink is indeed disul¢de-mediated (data not shown). As
the 75 kDa product did not react with antibodies against
SecE and SecG, and the appearance was accompanied by a
clear decrease of the SecY band (Fig. 4B, lanes 2 and 7), we
conclude that the observed crosslink products represent disul-
¢de-linked SecY dimers. It should be noted that SecY mutants
Fig. 1. Membrane topology model of E. coli SecY. The residues that were replaced by cysteine are indicated in black circles. The abbreviations
used for the cytoplasmic domains (C1 to C6) are indicated below. Endogenous cysteines at positions 329 and 385 have been replaced by a ser-
ine residue [7].
Fig. 2. F-Mal labeling of single cysteine SecY mutants. IMVs con-
taining overproduced single cysteine SecY mutants were incubated
with 0.25 mM F-Mal and analysed by 12% SDS^PAGE and in gel
UV £uorescence. SecY molecules modi¢ed with F-Mal are indicated
(SecY-F-Mal).
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S11C and S431C even form dimers without S4O6 that cannot
be completely dissociated by reduction with DTT (Fig. 4A,
lanes 2 and 7). This suggests that both the N- and C-termini
of neighbouring SecY molecules are in close proximity of each
other and therefore crosslink e⁄ciently.
3.4. ProOmpA translocation into IMVs containing
disul¢de-crosslinked SecY
To investigate whether disul¢de-linked SecY dimers are still
functional we assayed the oxidised SecY mutants for in vitro
translocation activity of proOmpA under non-reducing con-
ditions (OX). As a control we re-reduced the oxidised mutants
with DTT and performed translocation reactions under reduc-
ing conditions (RR). IMVs containing Cys-less SecYEG com-
plexes are equally active in proOmpA translocation under
non-reducing as under reducing conditions (Fig. 5, lanes 1
and 2). This shows that a direct comparison of the transloca-
tion activities under both conditions is legitimised. Oxidation
of SecY mutants S11C and S431C (domains C1 and C6) does
not a¡ect the translocation activity (Fig. 5, lanes 3, 4 and 7,
8), indicating that SecY molecules dimerised via the N- or C-
termini are still active. In contrast, oxidation of SecY mutant
S111C (domain C2) leads to a drastic inhibition of the trans-
location (Fig. 5, lane 5), demonstrating that translocation of
proOmpA is not allowed into IMVs containing SecY mole-
cules disul¢de-crosslinked via S111C. Translocation activity
can be restored upon cleavage of the disul¢de bond with
DTT, showing that crosslinking via SecY(S111C) only tran-
siently inactivates SecYEG (Fig. 5, lane 6).
3.5. Chemical crosslinking of SecY to SecG
Whereas oxidative crosslinking can only provide informa-
tion on close proximity of two cysteine residues, chemical
crosslinking can demonstrate many more intermolecular con-
tacts. We made use of the heterobifunctional crosslinker
S-MBS to probe for additional interactions around the intro-
duced cysteines. IMVs overexpressing the mutant SecYEG
complexes were incubated with S-MBS and analysed by
SDS^PAGE followed by immunodetection with anti-SecY
antibodies. SecY(S111C) and SecY(T179C) gave rise to a
50 kDa crosslink product (Fig. 6A, lanes 3 and 4). To identify
the product we analysed the samples by anti-SecE (data not
shown) and anti-SecG immunodetection (Fig. 6). Only the
SecG antibodies reacted with the 50 kDa product formed
upon crosslinking of SecY mutants S111C and T179C (Fig.
6B, lanes 2 and 3), con¢rming the identity of both products as
SecG crosslinked to SecY. This indicates that SecY domains
C2 and C3 are in close proximity of SecG. Due to the low
e⁄ciency of crosslinking we cannot determine the e¡ect of
SecY^SecG crosslinking on functionality of the SecYEG com-
plex.
4. Discussion
In this study we have investigated intermolecular interac-
tions at the cytoplasmic side of E. coli translocase by means of
Fig. 3. In vitro translocation activity of NEM and F-Mal-labeled
SecYEG complexes. IMVs containing overproduced single cysteine
SecY mutants were incubated in the absence (A) and presence of
1 mM NEM (B) or 0.25 mM F-Mal (C), re-isolated and assayed
for in vitro translocation of £uorescently labeled proOmpA. Trans-
location reactions were allowed to proceed for 7 min at 37‡C and
untranslocated proOmpA was digested by proteinase K. Protease-
protected material was separated by 12% SDS^PAGE and visualised
by in gel UV £uorescence. ProOmpA-F-Mal was used in (A) and
(B), proOmpA-AF633 was used in (C). Lanes 8 represent 10% of
the total amount of £uorescent proOmpA added to the transloca-
tion reactions.
Fig. 4. Disul¢de crosslinking of SecY. IMVs containing overpro-
duced single cysteine SecY mutants were reduced with 5 mM DTT
(A) or oxidised with 1 mM tetrathionate (S4O6) (B). Samples were
analysed by 10% SDS^PAGE followed by immunodetection with
antibodies raised against SecY. SecY monomers and SecY dimers
(SecY2) are indicated. The broad bands indicated by asterisks repre-
sent full length SecY disul¢de-linked to a 14 kDa C-terminal (*) or
24 kDa N-terminal (**) fragment of SecY [37]. The sharp band just
below (**) in A and B is an aspeci¢c cross-reaction of the SecY
antibodies.
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thiol chemistry experiments. In each cytoplasmic domain of
SecY we have introduced a single cysteine that is accessible
for thiol reactive probes and does not interfere with SecYEG
functionality. This provides us with a clean system to study
the e¡ect of structural changes in these domains caused by
chemical modi¢cation or crosslinking.
Cytoplasmic domain C5 of SecY is highly conserved and
based on studies with cold-sensitive SecY mutants, this region
has been proposed to be involved in an interaction with SecA
[18,19,38]. Chemical modi¢cation of SecY(S349C) in C5 with
NEM or F-Mal completely inhibits protein translocation (Fig.
3). This further stresses the importance of this domain for
functionality and in contrast to the previous mutagenesis
studies we can exclude that the aberrant behaviour observed
here is caused by misfolding of the domain during biogenesis
since the unmodi¢ed mutant is fully functional. Most likely,
chemical modi¢cation of SecY(S349C) disturbs the previously
proposed interaction site with SecA and thus prevents protein
translocation.
Despite extensive trials with each of the mutants using dif-
ferent cysteine-speci¢c crosslinkers and crosslinking condi-
tions, we were unable to observe any SecY crosslinks to
SecE, SecA or other proteins (E.O. van der Sluis, unpublished
results). The sensitivity for chemical modi¢cation of
SecY(S349C) can explain why we were unsuccessful in observ-
ing a SecY^SecA crosslink. First, the presence of a crosslinker
on SecY would disturb the interaction with SecA. Second,
binding of SecA to SecYEG would prevent the reaction of
the crosslinker with the cysteine, making this strategy ‘suici-
dal’.
An oligomeric organisation of SecYEG has been shown
with various techniques, but an interaction between two
SecY molecules was so far only demonstrated with an inter-
vening SecE dimer [8]. In this study we show that cysteine
residues in cytoplasmic domains C1, C2 and C6 of SecY
each have the ability to form a disul¢de bond with a neigh-
bouring SecY molecule (Fig. 4). Although it could be inferred
that the dimers we observe are caused by aspeci¢c interactions
between randomly colliding (monomeric) SecYEG protomers,
we think this is unlikely for the following reasons: ¢rst, we
have previously shown that disul¢de crosslinking within olig-
omeric SecYEG complexes is not induced by overexpression
as it also occurs at wild-type levels [8] ; second, disul¢de cross-
linking of SecY(S11C) and SecY(S431C) occurs spontane-
ously whilst membranes are kept at 4‡C which is far below
the phase transition temperature of the E. coli cytoplasmic
membrane and thus minimises lateral di¡usion of proteins
[39] ; third, disul¢de crosslinking is not observed with cysteine
mutants located in domains C4 and C5 which are of similar
size as C2 suggesting that the crosslinking is not merely
caused by high £exibility of these large domains. From this
we conclude that the observed SecY dimers truly re£ect close
spatial arrangements within an oligomeric SecYEG com-
plex.
From the e¡ect of disul¢de crosslinking on translocation
activity we can obtain more insight in the individual contri-
butions of these domains to protein translocation. SecY cross-
linked via S11C or S431C (domains C1 and C6) is equally
active as uncrosslinked SecY (Fig. 5). This shows that disul-
¢de crosslinking of SecY per se does not inactivate SecYEG
and that during the catalytic cycle of translocation, two SecY
N- or C-termini are allowed to remain in close proximity. This
constitutive proximity is re£ected by the spontaneous oxida-
tion to disul¢des observed with SecY mutants S11C and
S431C and is in agreement with an oligomeric organisation
of SecYEG during translocation as previously proposed
[4,10]. It should be noted that a disul¢de bond between two
N- or C-termini only leads to the formation of a loop struc-
ture that can still possess substantial conformational freedom.
In contrast, a disul¢de bond connecting two genuine loops
causes a much greater restraint on £exibility. Indeed, disul¢de
crosslinking of two SecY C2 domains inactivates the SecYEG
complex, showing that dynamics of these domains are re-
quired during translocation (Fig. 5). Previous experiments
have shown that disul¢de crosslinking of two SecE molecules
[7] or of SecY to SecE [8,16] inhibits protein translocation.
The transmembrane segment at the heart of these interactions
(TMS3 of SecE) is located at the interface of two SecYEG
Fig. 5. Translocation activity of oxidised and re-reduced SecYEG
complexes. SecY mutants capable of forming SecY dimers were as-
sayed for in vitro translocation activity of F-Mal-labeled proOmpA
as described in the legend to Fig. 3. Translocation reactions were
performed with oxidised membranes under non-reducing conditions
(OX), or with re-reduced membranes under reducing conditions
(RR) (for details see Section 2).
Fig. 6. Chemical crosslinking of SecY to SecG. IMVs containing
overproduced single cysteine SecY were incubated with 1 mM sulfo-
MBS (S-MBS) and analysed by 10% SDS^PAGE followed by im-
munodetection with antibodies raised against SecY (A). Single cys-
teine SecY mutants giving rise to a 50 kDa crosslink product were
analysed by immunodetection with antibodies raised against the
C-terminus of SecG. SecG and SecY crosslinked to SecG (SecYG)
are indicated (B). The asterisk indicates SecG crosslinked to an N-
terminal fragment of SecY.
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protomers [8]. One of the transmembrane segments anchoring
the C2 domain (TMS2 of SecY) has been shown to contact
TMS3 of SecE directly [8]. We therefore propose that the C2^
C2 disul¢de bridge spans the same interface between two
SecYEG protomers and that it inactivates SecYEG in a sim-
ilar manner as the SecE^SecE and the SecY^SecE crosslinks.
Interestingly, all three SecY mutants capable of forming
disul¢de-linked homodimers (S11C, S111C and S431C in do-
mains C1, C2 and C6, respectively) are moderately sensitive
for chemical modi¢cations. NEM modi¢cation has no e¡ect
on functionality and F-Mal only partially inactivates these
mutants (Fig. 3). This suggests that the nature of the inter-
action disturbed upon modi¢cation of the latter mutants is
di¡erent from that leading to complete inactivation of
SecY(S349C). Electron microscopy and BN-PAGE studies
have revealed that SecYEG is a conformationally dynamic
structure that can exist in multiple oligomeric isoforms
[4,10]. Furthermore, it was shown that dimeric SecA recruits
multiple SecYEG protomers into a tetrameric assembly that
was proposed to represent the functional complex [4]. Bio-
chemical studies with aspeci¢c crosslinkers, however, failed
to demonstrate inter-protomer crosslinks [10,11,17]. This
was explained by the reaction of the crosslinkers with amino
acyl side chains involved in the association of SecYEG pro-
tomers, thereby disturbing their association [10]. Modi¢cation
of the cysteines in SecY domains C1, C2 or C6 could lead to a
similarly disturbed interaction. The decrease in translocation
activity would thus be caused by disturbed assembly of
SecYEG protomers into their functional organisation. Since
interactions between SecYEG protomers also take place in the
membrane region [8] and are expected in the periplasmic re-
gion, disturbance of only a cytoplasmic interaction is not
likely to completely prevent association of SecYEG protomers
and therefore only partial inactivation of these mutants is
observed.
Several biochemical studies have shown that SecG associ-
ates with SecYE [28,29], but the domains of SecY or SecE
involved in an interaction with SecG were unknown. In this
study, we show that SecY domains C2 and C3 are in close
proximity to SecG. Since SecG is not essential, it is likely to
be located at the periphery of a SecYEG protomer. A bio-
chemical indication for such peripheral localisation of SecG is
the crosslink to S111C of SecY which is located close to the
interface of two SecYEG protomers. Recent BN-PAGE ex-
periments showed that overproduced SecYEG forms dimeric
and tetrameric multimers in addition to monomers, whereas
SecYE only forms monomers and dimers [10]. These SecG
dependent tetrameric multimers appeared more stable and
less dynamic than the dimeric SecYEG complexes. In this
light it is interesting to observe that SecG crosslinks to a
region of SecY involved in SecYEG oligomerisation. Thus,
SecG might directly a¡ect the oligomerisation of SecYEG.
The dimeric form of SecG could be related to this oligomer-
isation [32].
Taken together, the data presented in this study further
increase our insight in the structure and the function of
SecYEG translocase. This will be useful in interpreting me-
dium resolution 3D structures of SecYEG that are expected in
the near future [9].
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